Taubman leukemia researcher wins 2014 Award for Excellence in Medical Science Translational -
A physician-scientist who has developed a personalized immunotherapy for T cell leukemia own using patient is the recipient of the 2014 Taubman Prize for excellence in translational medical science, awarded by the medical research Institute A. Alfred Taubman at the University of Michigan medical School.
Carl June, MD from the Perelman School of Medicine of the University of Pennsylvania will receive the award of $ 100,000 in recognition of the treatment, he designed what is credited as the first successful demonstration of sustainable the use of gene transfer therapy to transform immune cells of the own body arms for cancerous tumors.
research is considered a historic breakthrough in the treatment of blood cancers that have stopped responding to conventional therapies, or for patients who are not candidates for a bone marrow transplant, which present a risk high mortality.
"Dr. June visionary approach has transformed the scientific approach of these cancers and brought hope to patients who have had little or no" said Eva Feldman, MD, Ph.D., Director of the Taubman Institute. " We are honored to recognize extraordinary contributions by awarding him the Taubman price. "
June was chosen by a national panel of experts in medical sciences prominent among dozens of candidates for the Taubman Prize. His groundbreaking work has shown that T cells modified in the laboratory for a protein of like-antibodies called a chimeric antigen receptor (CAR), can be re-injected into the blood of a patient, where the new cells "hunters" seek and attack cancer cells. These T cells also have specific domain signaling that help to reproduce, which expands the "army" of cells available for the fight against cancer.
results of the first three patients to join a clinical trial of immunotherapy that were published in 2011 . updated results on the 59 first trial patients presented in December 2013 showed that almost half of chronic lymphocytic leukemia patients responded to therapy, and nearly 0 percent of patients with acute lymphoblastic leukemia - there including children and adults -. in remission after receiving therapy
June, Professor Richard W. Vague Immunotherapy, Department of Pathology and Laboratory Medicine at the Perelman School of Medicine, will present the keynote address at the annual conference of the Taubman Institute October 10, 2014 at the Auditorium Kahn on the University of Michigan Ann Arbor campus. The symposium is open to the public.
M .. A. Alfred Taubman, founder and president of Taubman Institute, will present the award.
"Translating medical research on treatments and cures is the actual work that the Taubman Institute was established to promote and reward," said Taubman. "There is no better example today that Dr. June has done for leukemia patients, and we are delighted to recognize his amazing achievements."
The Taubman Prize was established in 2012 to recognize outstanding translational medical research beyond the University of Michigan. It includes a $ 100,000 prize and is presented annually to non-UM clinician-scientist who has done most to transform laboratory discoveries into clinical applications for patients suffering from the disease
previous winners are :.
2013: Brian Druker, MD of Oregon Health & Science University and Charles Sawyers, MD Memorial Sloan Kettering Cancer Center, for their discoveries related to chronic myeloid leukemia
.: 2012 Hal Dietz, MD, of Johns Hopkins University for his discoveries related to connective tissue disease.
EmoticonEmoticon